Moderna reports fourth quarter and fiscal year 2023 financial results and provides business updates

Posts fourth quarter revenues of $2.8 billion, gaap net income of $217 million and gaap diluted eps of $0.55 reports full-year revenues of $6.8 billion, gaap net loss of $(4.7) billion and gaap diluted eps of $(12.33); loss primarily driven by mostly non-cash charges of $3.7 billion related to resizing and a tax valuation allowance reaffirms 2024 expected product sales of approximately $4 billion expects regulatory approvals for its investigational rsv vaccine for older adults beginning in first half of 2024, and anticipates additional key milestones from its late-stage pipeline this year cambridge, ma / accesswire / february 22, 2024 / moderna, inc. (nasdaq:mrna) today reported financial results and provided business updates for the fourth quarter and fiscal year 2023. "2023 was a year of transition for moderna as we adapted to the endemic market.
MRNA Ratings Summary
MRNA Quant Ranking